Precision Biosciences (DTIL) Cash from Operations (2018 - 2026)
Precision Biosciences (DTIL) posted quarterly Cash from Operations of 11937000.0 for Q1 2026, up 37.35% year-over-year from 8691241.79 in Q1 2025, and down 6.11% quarter-over-quarter from 11250000.0 in Q4 2025.
Precision Biosciences (DTIL) Cash from Operations (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Cash from Operations for 9 consecutive years, with 11937000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 37.35% year-over-year to 11937000.0; the TTM figure through Mar 2026 stood at 58728000.0 (changed 0.36% YoY), while the FY2025 annual figure was 65843000.0, down 12.66% from the prior year.
- Cash from Operations retreated to 11937000.0 in Q1 2026 per DTIL's latest filing, from 11250000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 29186000.0 in Q3 2022 and bottomed at 31464000.0 in Q1 2023.
- Historically, Cash from Operations has averaged 15652470.59 across 5 years, with a median of 18981000.0 in 2024.
- Annual changes were most pronounced in 2022 — Cash from Operations surged 222.09% — and 2023, when it slumped 179.12%.
- Precision Biosciences' Cash from Operations stood at 21843000.0 in 2022, then soared by 61.44% to 8423000.0 in 2023, then sank by 121.81% to 18683000.0 in 2024, then soared by 39.78% to 11250000.0 in 2025, then decreased by 6.11% to 11937000.0 in 2026.
- Business Quant data shows DTIL's Cash from Operations at 11937000.0 in Q1 2026, 11250000.0 in Q4 2025, and 15270000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Precision Biosciences | 228.31 Mn | 140.77 Mn | - | -13.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -13.44 Mn |
| Jun 30, 2026 | -13.44 Mn |
| Mar 31, 2026 | -11.94 Mn |
| Mar 31, 2026 | -11.94 Mn |
| Dec 31, 2025 | -11.25 Mn |
| Dec 31, 2025 | -11.25 Mn |
| Sep 30, 2025 | -15.27 Mn |
| Sep 30, 2025 | -15.27 Mn |
| Jun 30, 2025 | -20.27 Mn |
| Jun 30, 2025 | -20.27 Mn |
| Mar 31, 2025 | -19.05 Mn |
| Mar 31, 2025 | -19.05 Mn |
| Dec 31, 2024 | -18.68 Mn |
| Dec 31, 2024 | -18.68 Mn |
| Sep 30, 2024 | -5.91 Mn |
| Sep 30, 2024 | -5.91 Mn |
| Jun 30, 2024 | -14.87 Mn |
| Jun 30, 2024 | -14.87 Mn |
| Mar 31, 2024 | -18.98 Mn |
| Mar 31, 2024 | -18.98 Mn |